Zacks Research Brokers Increase Earnings Estimates for IRWD

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Equities research analysts at Zacks Research increased their Q2 2025 EPS estimates for shares of Ironwood Pharmaceuticals in a research note issued on Thursday, May 1st. Zacks Research analyst R. Department now forecasts that the biotechnology company will post earnings per share of $0.03 for the quarter, up from their prior forecast of $0.01. The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals' Q4 2025 earnings at $0.12 EPS, FY2025 earnings at $0.21 EPS, Q1 2026 earnings at $0.04 EPS, Q2 2026 earnings at $0.07 EPS, Q3 2026 earnings at $0.10 EPS, Q4 2026 earnings at $0.08 EPS, FY2026 earnings at $0.30 EPS, Q1 2027 earnings at $0.03 EPS and FY2027 earnings at $0.12 EPS.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.08). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The business had revenue of $90.55 million for the quarter, compared to analyst estimates of $93.85 million.

A number of other equities analysts have also issued reports on the stock. Jefferies Financial Group reiterated a "hold" rating and issued a $0.70 target price (down previously from $8.00) on shares of Ironwood Pharmaceuticals in a research report on Tuesday, April 15th. Citizens Jmp lowered shares of Ironwood Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research note on Monday, April 14th. JMP Securities decreased their price target on Ironwood Pharmaceuticals from $23.00 to $14.00 and set a "market outperform" rating for the company in a research note on Thursday, January 30th. Leerink Partners dropped their price objective on Ironwood Pharmaceuticals from $3.00 to $1.00 and set a "market perform" rating on the stock in a research note on Monday, April 14th. Finally, Craig Hallum cut Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 16th. Eight equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, Ironwood Pharmaceuticals has a consensus rating of "Hold" and a consensus target price of $4.78.

Ironwood Pharmaceuticals Stock Performance

Shares of NASDAQ:IRWD traded down $0.00 on Monday, hitting $0.93. The company's stock had a trading volume of 1,388,802 shares, compared to its average volume of 2,554,943. Ironwood Pharmaceuticals has a 12 month low of $0.59 and a 12 month high of $8.23. The stock's 50-day moving average is $1.21 and its two-hundred day moving average is $2.74. The company has a market capitalization of $149.98 million, a price-to-earnings ratio of -30.90 and a beta of 0.37.

Insiders Place Their Bets

In related news, CEO Thomas A. Mccourt sold 139,064 shares of the company's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $1.76, for a total value of $244,752.64. Following the completion of the sale, the chief executive officer now owns 1,160,634 shares in the company, valued at approximately $2,042,715.84. This represents a 10.70 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CMO Michael Shetzline sold 41,269 shares of the business's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $1.76, for a total transaction of $72,633.44. Following the sale, the chief marketing officer now directly owns 554,007 shares in the company, valued at approximately $975,052.32. This trade represents a 6.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 192,381 shares of company stock worth $338,591. Company insiders own 12.90% of the company's stock.

Institutional Trading of Ironwood Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. Pacer Advisors Inc. boosted its stake in shares of Ironwood Pharmaceuticals by 4.0% during the 4th quarter. Pacer Advisors Inc. now owns 11,730,771 shares of the biotechnology company's stock valued at $51,967,000 after buying an additional 450,949 shares during the period. Renaissance Technologies LLC grew its stake in Ironwood Pharmaceuticals by 5.5% in the fourth quarter. Renaissance Technologies LLC now owns 9,066,241 shares of the biotechnology company's stock valued at $40,163,000 after purchasing an additional 469,043 shares in the last quarter. Geode Capital Management LLC grew its stake in Ironwood Pharmaceuticals by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 3,306,570 shares of the biotechnology company's stock valued at $14,652,000 after purchasing an additional 13,028 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in Ironwood Pharmaceuticals by 4.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,983,240 shares of the biotechnology company's stock worth $8,786,000 after purchasing an additional 78,969 shares during the last quarter. Finally, Northern Trust Corp raised its stake in shares of Ironwood Pharmaceuticals by 7.9% during the 4th quarter. Northern Trust Corp now owns 1,625,110 shares of the biotechnology company's stock worth $7,199,000 after purchasing an additional 118,962 shares in the last quarter.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.